FRMSL (4746) reported revenue of NT$497.9 million for Oct 2026, +24.0% year on year and +1.7% from the previous month. Revenue for Jan–Oct 2026 was NT$4.01 billion (+1.6% year on year).
Year-on-year revenue growth: 5 months in a row. →
In Oct 2026, it ranked No. 18 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$497.9 million | +24.0% | +1.7% |
| Sep 2026 | NT$489.6 million | +17.2% | +6.3% |
| Aug 2026 | NT$460.6 million | +25.7% | +18.6% |
| Jul 2026 | NT$388.2 million | +3.1% | -8.0% |
| Jun 2026 | NT$421.9 million | +0.3% | +17.6% |
| May 2026 | NT$358.7 million | -4.9% | +8.5% |
| Apr 2026 | NT$330.5 million | -25.7% | -27.5% |
| Mar 2026 | NT$456 million | -6.0% | +95.9% |
| Feb 2026 | NT$232.7 million | -20.5% | -38.0% |
| Jan 2026 | NT$375.3 million | +2.5% | -28.7% |
| Dec 2025 | NT$526.6 million | -2.4% | +40.0% |
| Nov 2025 | NT$376 million | -12.8% | -6.4% |
| Oct 2025 | NT$401.6 million | +5.4% | -3.9% |
| Sep 2025 | NT$417.8 million | +14.4% | +14.0% |
| Aug 2025 | NT$366.4 million | +8.4% | -2.7% |
| Jul 2025 | NT$376.4 million | +14.9% | -10.5% |
| Jun 2025 | NT$420.6 million | -3.9% | +11.5% |
| May 2025 | NT$377.2 million | -17.0% | -15.2% |
| Apr 2025 | NT$445 million | +38.0% | -8.2% |
| Mar 2025 | NT$484.9 million | -13.9% | +65.7% |
| Feb 2025 | NT$292.6 million | +19.1% | -20.1% |
| Jan 2025 | NT$366.1 million | +12.6% | -32.1% |
| Dec 2024 | NT$539.4 million | +9.1% | +25.1% |
| Nov 2024 | NT$431.1 million | +36.7% | +13.1% |
| Oct 2024 | NT$381.1 million | -5.3% | +4.3% |
Jan–Oct 2026 cumulative: NT$4.01 billion (+1.6% YoY)
Other Biotech & Medical companies
Compare with peers: FRMSL vs PEC / FRMSL vs Lotus Pharm / FRMSL vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16